Pancreatic volume in type 1 und type 2 diabetes mellitus

Goda, Koshi; Sasaki, Eun; Nagata, Koji; Fukai, Mina; Ohsawa, Nakaaki; Hahafusa, T.

doi:10.1007/s005920170012

Cited by 103 publications

(108 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pancreas appeared altered on these images with large degrees of fatty infiltration, there was no difference in the overall size of the pancreas between the patients and healthy volunteers. This observation is consistent with that of Goda et al (13), who found a significantly lower pancreatic volume for patients with type 1 diabetes but no difference in the pancreas volume of patients with type 2 diabetes compared with healthy controls as measured from computed tomography (CT) images. Despite the differences in appearance and baseline T 1 value there were no significant differences in functional kinetic parameters between the normal volunteers and the patients.…”

Section: Discussionsupporting

confidence: 92%

Multiple‐bolus dynamic contrast‐enhanced MRI in the pancreas during a glucose challenge

Naish

Hutchinson

Caunce

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To assess the feasibility of multiple-bolus dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in the pancreas; to optimize the analysis; and to investigate application of the method to a glucose challenge in type 2 diabetes. Materials and Methods:A 4-bolus DCE-MRI protocol was performed on five patients with type 2 diabetes and 11 healthy volunteers during free-breathing. Motion during the dynamic time series was corrected for using a model-driven nonlinear registration. A glucose challenge was administered intravenously between the first and second DCE-MRI acquisition in all patients and in seven of the healthy controls.Results: Image registration improved the reproducibility of the DCE-MRI model parameters across the repeated bolus-acquisitions in the healthy controls with no glucose challenge (eg, coefficient of variation for K trans improved from 38% to 28%). Native tissue T 1 was significantly lower in patients (374 6 68 msec) compared with volunteers (519 6 41 msec) but there was no significant difference in any of the baseline DCE-MRI parameters. No effect of glucose challenge was observed in either the patients or healthy volunteers. Conclusion:Multiple bolus DCE-MRI is feasible in the pancreas and is improved by nonlinear image registration but is not sensitive to the effects of an intravenous glucose challenge.

show abstract

Section: Discussionsupporting

confidence: 92%

Multiple‐bolus dynamic contrast‐enhanced MRI in the pancreas during a glucose challenge

Naish

Hutchinson

Caunce

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…While our primary focus was on indicators of vascular integrity and leukocyte infiltration, we also measured pancreas volume, given that pancreatic atrophy is a characteristic observation in long-standing T1D, as evidenced by examination of pancreas volume at autopsy, by ultrasound, by CT, or via MRI (10)(11)(12)(13). To control for the influences of body build on pancreatic volume, we calculated a pancreatic volume index (PVI) by dividing the pancreatic volume by body-surface area (12,14).…”

Section: Resultsmentioning

confidence: 99%

“…To control for the influences of body build on pancreatic volume, we calculated a pancreatic volume index (PVI) by dividing the pancreatic volume by body-surface area (12,14). Mean PVI of the patients was 31% less than that of the controls ( Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients

et al. 2011

View full text Add to dashboard Cite

Type 1A diabetes (T1D) is an autoimmune disease characterized by leukocyte infiltration of the pancreatic islets of Langerhans. A major impediment to advances in understanding, preventing, and curing T1D has been the inability to "see" the disease initiate, progress, or regress, especially during the occult phase. Here, we report the development of a noninvasive method to visualize T1D at the target organ level in patients with active insulitis. Specifically, we visualized islet inflammation, manifest by microvascular changes and monocyte/macrophage recruitment and activation, using magnetic resonance imaging of magnetic nanoparticles (MNPs). As a proof of principle for this approach, imaging of infused ferumoxtran-10 nanoparticles permitted effective visualization of the pancreas and distinction of recent-onset diabetes patients from nondiabetic controls. The observation that MNPs accumulate in the pancreas of T1D patients opens the door to exploiting this noninvasive imaging method to follow T1D progression and monitoring the ability of immunomodulatory agents to clear insulitis.

show abstract

“…All of the other subjects were prepubertal. Because pancreatic size is influenced by the body surface area, we also calculated the pancreatic volume index, where we divided the estimated pancreatic volume by the body surface area (8).…”

Section: Methodsmentioning

confidence: 99%

“…␤-Cells, which are central in the development of diabetes, constitute the major part of the islets (1). There are reports in diabetic subjects of pathological changes involving not only the islets but the entire pancreatic gland, such as pancreatic volume reduction (2)(3)(4)(5)(6)(7)(8) and lipomatosis (fatty infiltration) of the pancreas (9,10). The lipomatosis reported in autopsy studies has been described as patchy intralobular or perilobular areas of fat replacement of pancreatic parenchyma (9,10).…”

mentioning

confidence: 99%

Pancreatic Lipomatosis Is a Structural Marker in Nondiabetic Children With Mutations in Carboxyl-Ester Lipase

et al. 2007

View full text Add to dashboard Cite

Both pancreatic volume reduction and lipomatosis have been observed in subjects with diabetes. The underlying molecular and pathological mechanisms are, however, poorly known, and it has been speculated that both features are secondary to diabetes. We have recently described pancreatic atrophy and lipomatosis in diabetic subjects of two Norwegian families with a novel syndrome of diabetes and exocrine pancreatic dysfunction caused by heterozygous carboxyl-ester lipase (CEL) mutations. To explore the early pathological events in this syndrome, we performed radiological examinations of the pancreas in nondiabetic mutation carriers with signs of exocrine dysfunction. In a case series study at a tertiary hospital, we evaluated 11 nondiabetic and mutation-positive children with fecal elastase deficiency and 11 age-and sex-matched control subjects using ultrasound and magnetic resonance imaging (MRI) to estimate pancreatic fat content. The pancreata of nondiabetic mutation carriers exhibited increased reflectivity on ultrasound and had MRI findings indicative of lipomatosis. Apparently, carriers of heterozygous CEL mutations accumulate fat in their pancreas before the anticipated development of diabetes. Our findings suggest that lipomatosis of the pancreas reflects early events involved in the pathogenesis of diabetes and exocrine pancreatic dysfunction syndrome. Diabetes 56: 444 -449, 2007 T he pancreas consists of acinar and ductal cells with the islets of Langerhans scattered within the exocrine tissue. ␤-Cells, which are central in the development of diabetes, constitute the major part of the islets (1). There are reports in diabetic subjects of pathological changes involving not only the islets but the entire pancreatic gland, such as pancreatic volume reduction (2-8) and lipomatosis (fatty infiltration) of the pancreas (9,10). The lipomatosis reported in autopsy studies has been described as patchy intralobular or perilobular areas of fat replacement of pancreatic parenchyma (9,10). Pancreatic size reduction and lipomatosis have been discussed as possible secondary events involved in atrophy and lipomatosis related to diabetes due to a reduced insulinotropic effect on the acinar cells (11-13). The underlying molecular and pathophysiological mechanisms are, however, poorly known. Monogenic pancreatic diseases could cast important light on early pathological events and provide the opportunity to study subjects before the development of diabetes.We recently described pancreatic atrophy and lipomatosis in diabetic subjects of two Norwegian families with a novel syndrome of diabetes and pancreatic exocrine dysfunction (MODY8; OMIM [Online Mendelian Inheritance in Man] no. 609812) caused by heterozygous carboxyl-ester lipase (CEL) mutations (14). In that report, computerized tomography of the pancreas was performed in adult mutation carriers, and most of the studied subjects were already diabetic. We hypothesized that the morphologic abnormalities of the pancreas that were identified, particularly the lipomatosis,...

show abstract

Pancreatic volume in type 1 und type 2 diabetes mellitus

Cited by 103 publications

References 29 publications

Multiple‐bolus dynamic contrast‐enhanced MRI in the pancreas during a glucose challenge

Multiple‐bolus dynamic contrast‐enhanced MRI in the pancreas during a glucose challenge

Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients

Pancreatic Lipomatosis Is a Structural Marker in Nondiabetic Children With Mutations in Carboxyl-Ester Lipase

Contact Info

Product

Resources

About